Loading…
Loading…
NAUT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for NAUT and 80,000+ other tickers.
See exactly how NAUT's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NAUT and 80,000+ other tickers.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding…
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT - Get Free Report) was the target of unusually large options trading on Monday. Stock traders bought 3,253 call options on the stock. This represents an increase of 1,427% compared to the average daily volume of 213 call options. Nautilus Biotechnology Stock Performance NAUT stock traded up $0.34 during midday trading
You can't buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas
NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access revenue remains too limited to prove it can turn into recurring sales. Unfortunately, the main risks going forward are still tied to potential execution setbacks, its ongoing cash burn, and a likely capital raise by 2027.